Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Download Mobile App




Blood Test Measures Amyloid Seeding Activity to Detect Alzheimer’s Disease

By LabMedica International staff writers
Posted on 25 Aug 2026

Early, accurate diagnosis of Alzheimer’s disease (AD) remains challenging in routine practice, despite its role as the leading cause of dementia worldwide. More...

Confirmation typically relies on cerebrospinal fluid testing (CSF) or positron emission tomography (PET), approaches that may be invasive, costly, or limited in availability. Although blood biomarkers are advancing rapidly, few directly measure amyloid beta (Aβ) aggregation seeding activity, a core process in AD pathology. Addressing this gap, a new study shows that plasma Aβ seeding activity measured with an ultrasonic amplification assay can accurately identify AD and mild cognitive impairment (MCI) due to AD.

Researchers at Xuanwu Hospital of Capital Medical University (Beijing, China) developed a blood-based diagnostic method using real-time ultrasonic protein misfolding cyclic amplification (PMCA) to detect plasma Aβ aggregation seeding activity. The findings were published online in the Chinese Medical Journal on June 16, 2026. In a two-stage study, the assay accurately identified AD and MCI due to AD, with diagnostic accuracy exceeding 90% in the validation cohort.

The method integrates ultrasonic and fluorescence techniques to track Aβ aggregation kinetics in real time and completes detection within 24 hours. It was applied for the first time to measure plasma Aβ seeding activity and, according to the team, can detect Aβ oligomers at concentrations as low as 1 femtomole. The authors attribute its sensitivity and speed to ultrasonic cavitation, where energy at spherical interfaces promotes fibril formation, and localized heat and shear induce misfolding, markedly increasing amplification efficiency.

The study used a rigorous two-stage design. A discovery phase enrolled 120 participants to establish preliminary diagnostic efficacy. An independent validation phase included 429 participants comprising cognitively normal individuals, patients with MCI due to AD, patients with AD, and patients with non-AD dementias; immunodepletion experiments confirmed that the measured signal was specifically induced by Aβ seeds in plasma.

In the validation cohort, plasma Aβ seeding activity was significantly higher in AD than in cognitively normal individuals and in non-AD dementia (P < 0.001). Individuals with MCI due to AD also showed elevated seeding activity, supporting earlier-stage identification. Receiver operating characteristic (ROC) analyses yielded areas under the curve (AUCs) of 0.93 (AD vs. cognitively normal), 0.91 (AD vs. non-AD dementia), 0.92 (MCI due to AD vs. cognitively normal), and 0.90 (MCI due to AD vs. non-AD dementia).

According to the authors, the minimally invasive assay could support large-scale community and primary care screening, differentiation of AD from other dementias, assessment of disease severity, and monitoring of progression. They also note potential use as an objective biomarker for participant selection and efficacy evaluation in clinical trials, and plan larger-scale validation with long-term follow-up to evaluate prediction of disease course.

“The most important significance of this study lies in providing clinicians with a minimally invasive, efficient, and accurate AD diagnostic tool,” said Prof. Jianping Jia of Xuanwu Hospital of Capital Medical University.


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
MR-proADM Test
B•R•A•H•M•S MR-proADM KRYPTOR test
Gold Member
Automatic Hematology Analyzer
CF9600
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: A new study links broad genomic sequencing before first-line therapy to longer survival, supporting its role in treatment decisions (Image Credit: Shutterstock)

Study Supports Broad Genomic Profiling Before First-Line Lung Cancer Treatment

Biomarker testing plays a critical role in advanced non-small cell lung cancer by identifying patients who may benefit from targeted therapies. However, testing only one or two genes can miss actionable... Read more

Immunology

view channel
Image: The findings underscore the importance of aligning allergy testing with clinical history and diagnostic guidelines to reduce inappropriate testing and its consequences (Image Credit: iStock)

Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice

Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more

Industry

view channel
Image Credit: iStock

C2N Makes PrecivityAD2 Alzheimer’s Blood Test Available to Clinicians

Diagnosing Alzheimer’s disease can be challenging, particularly in patients with mild cognitive impairment or early dementia. Assessing brain amyloid pathology can guide clinical decisions, but diagnostic... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.